Completed

Pattern Of Use Of Belatacept In US Transplant Recipients

What is being collected

Data Collection

Collected from past medical records and data - Retrospective

Who is being recruted

See all eligibility criteria

How is the trial designed

Cohort

Tracking disease incidence in order to identify risk factors and understand disease progression over time.

Observational

Study Start: January 2012

See protocol details

Summary

Principal SponsorBristol-Myers Squibb

Last updated: July 13, 2018

Sourced from a government-validated database.Claim as a partner

Study start date: January 31, 2012

Actual date on which the first participant was enrolled.

The prevalence of Belatacept use The characteristics of Belatacept users and the temporal trends in these characteristics Characteristics of adult kidney-only transplant recipients who are treated with Belatacept vs. who are treated with Calcineurin inhibitors (CNI)-based regimens at the time of transplantation, and the temporal trends in these characteristics during 7 years post approval of Belatacept.

NCT01670058

Principal SponsorBristol-Myers Squibb

Last updated: July 13, 2018

Sourced from a government-validated database.Claim as a partner

Protocol

This section provides details of the study plan, including how the study is designed and what the study is measuring.

Design Details

5000 patients to be enrolled

Total number of participants that the clinical trial aims to recruit.

Cohort

These studies follow a group of individuals with common characteristics (such as a condition or birth year) over a specific period to study health outcomes or exposures.

Eligibility

Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.

Criteria

Any sex

Biological sex of participants that are eligible to enroll.

Healthy volunteers not allowed

If individuals who are healthy and do not have the condition being studied can participate.

Criteria

For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com. Inclusion Criteria: The cohort for the analyses of all transplants includes all organ transplant recipients who are reported with Belatacept at transplant Exclusion Criteria:

Study Plan

Find out more about all the medication administered in this study, their detailed description and what they involve.

Treatment Groups

Study Objectives

2 intervention groups are designated in this study

This study does not include a placebo group

Treatment Groups

Study Objectives

Primary Objectives

Secondary Objectives

Study Centers

These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.

This study has no location dataSave this study to your profile to know when the location data is available.

CompletedNo study centers